Ginkgo Bioworks Secures $47M Contract to Build Automated Phenotyping Platform
Written by Emily J. Thompson, Senior Investment Analyst
Source: PRnewswire
Updated: 1 hour ago0mins
- Significant Contract Value: Ginkgo Bioworks has secured a four-year contract worth up to $47 million with PNNL to co-design and build a High-Throughput Automated Phenotyping Platform, enhancing U.S. competitiveness in the bioeconomy.
- Technological Innovation: The platform will leverage modular automation and flexible software to automate end-to-end workflows from media to sample preparation, expected to significantly increase throughput and reproducibility of microbial phenotyping campaigns.
- Strategic Collaboration: By partnering with PNNL, Ginkgo Bioworks aims to expand access to high-quality biological phenotyping at scale, providing datasets necessary for modern AI methods and driving scientific innovation.
- National Security Assurance: This project supports the Department of Energy's Biological and Environmental Research program, ensuring the U.S. maintains global leadership in biotechnology innovation while safeguarding economic, societal, and national security benefits.
DNA.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on DNA
Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 11.50 USD with a low forecast of 9.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
0 Hold
3 Sell
Moderate Sell
Current: 9.210
Low
9.00
Averages
11.50
High
14.00
Current: 9.210
Low
9.00
Averages
11.50
High
14.00
BTIG
Sell
maintain
$6 -> $9
2025-08-25
Reason
BTIG
Price Target
$6 -> $9
2025-08-25
maintain
Sell
Reason
BTIG raised the firm's price target on Ginkgo Bioworks to $9 from $6 but keeps a Sell rating on the shares. The firm cites the company's "significant' Q2 topline beat as it was able to take out costs faster than expected, the analyst tells investors in a research note. BTIG notes however that while Ginkgo reiterated that reaching adjusted EBITDA breakeven by 2026-end is its number one goal, it will be a "close one" if Ginkgo can hit its EBITDA positivity target given the lack of visibility on the growth outlook of the business in 2026.
TD Cowen
Buy
upgrade
$12 -> $16
2025-08-08
Reason
TD Cowen
Price Target
$12 -> $16
2025-08-08
upgrade
Buy
Reason
TD Cowen raised the firm's price target on Ginkgo Bioworks to $16 from $12 and keeps a Buy rating on the shares. The firm said Cell Engineering drove the Q2 beat despite softer biosecurity revenues.
See All Ratings
About DNA
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?